Serum Irisin In Individuals with Type 2 Diabetes Mellitus and Prediabetes in Duhok City


Type 2 Diabetes Mellitus

How to Cite

Ibrahim, I., & Salih, S. (2022). Serum Irisin In Individuals with Type 2 Diabetes Mellitus and Prediabetes in Duhok City. Journal of Life and Bio Sciences Research , 3(02), 59 - 64.


Type 2 diabetes mellitus is one of the most common chronic metabolic diseases characterized by hyperglycemia, with either lack of insulin secretion or decreased sensitivity to insulin metabolic effects. Prediabetes is an intermediate stage between normal glucose metabolism and diabetes mellitus with high prevalence rate of diabetes mellitus developments. We aimed in this study to evaluate serum irisin level among patients with type 2 diabetes mellitus and individuals with prediabetes. A cross-sectional study was done on 214 participants, who were attend to the Azadi Teaching Hospital, Diabetic unit at Duhok city between October 2021 and April 2022. The participants were classified to three groups; 94 patients with type 2 diabetes mellitus, 60 prediabetic individuals and 60 apparently healthy control. We collected blood samples in the morning after overnight fasting from all participants. All parameters were measured by cobas 6000 (Hitachi, Roche) and including glucose, insulin, total cholesterol, triglyceride, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and blood HbA1c% except serum irisin that was measured by ELISA instrument. Serum irisin levels was lower in type 2 diabetic patients and prediabetic individuals compared to healthy control (P<0.001). There was a negative relation between serum irisin and total cholesterol, triglyceride, low-density lipoprotein-cholesterol, poor glycemic control and atherogenic indices, with positive relation of serum irisin with high-density lipoprotein-cholesterol -c. We found lower level of circulating serum irisin in type 2 diabetic patients and prediabetic individuals compared to healthy controls.


Afroz, A., Ali, L., Karim, M., Alramadan, M.J., Alam, K., Magliano, D.J., and Billah, B. (2019). Glycaemic control for people with type 2 diabetes mellitus in Bangladesh-an urgent need for optimization of management plan. Scientific Reports, 9(1), 1-10.

Akour, A., Kasabri, V., Boulatova, N., Bustanji, Y., Naffa, R., Hyasat, D., Momani, M. (2017). Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. Acta Diabetologica, 54(2), 163-170.

American Diabetes Association. ADA. (2003). Management of dyslipidemia in adults with diabetes. Diabetes care, 26(suppl_1), s83-s86.

American Diabetes Association. ADA. Classification and Diagnosis of Diabetes: Standards of medical Care in Diabetes-2021. Diabetes Care. 2021 Jan .44 (Suppl 1); S15-S33.

Aroda, V.R., and Ratner, R. (2008). Approach to the patient with prediabetes. The Journal of Clinical Endocrinology & Metabolism, 93(9), 3259-3265.

Aune, D., Norat, T., Leitzmann, M., Tonstad, S., and Vatten, L.J. (2015). Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis. European journal of epidemiology, 30(7), 529-542.

Bhowmik, B., Siddiquee, T., Mujumder, A., Afsana, F., Ahmed, T., Mdala, I.A., Omsland, T.K. (2018). Serum lipid profile and its association with diabetes and prediabetes in a rural Bangladeshi population. International Journal of Environmental Research and Public Health, 15(9), 1944.

Bostrom P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., Rasbach, K.A., Bostrom, E.A., Choi, J.H., Long, J.Z. (2012) A PGC1 -alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481(7382), 463-468, 2012.

Casadei, K., Kiel, J. (2021). Anthropometric Measurement In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing:30726000.

de la Iglesia, R., Lopez-Legarrea, P., Crujeiras, A.B., Pardo, M., Casanueva, F. F., Zulet, M.A., Martinez, J.A. (2014). Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clinical Endocrinology, 81(2), 306-311.

Duran, I.D., Gulcelik, N.E., Unal, M., Topcuoglu, C., Sezer, S., Tuna, M.M., Guler, S. (2015). Irisin levels in the progression of diabetes in sedentary women. Clinical Biochemistry, 48(18), 1268-1272.

Ebert, T., Kralisch, S., Wurst, U., Scholz, M., Stumvoll, M., Kovacs, P., Tonjes, A. (2016). Association of metabolic parameters and rs726344 in FNDC5 with serum irisin concentrations. International Journal of Obesity, 40(2), 260-265.

Goldberg, I.J. (2001). Diabetic dyslipidemia: causes and consequences. The Journal of Clinical Endocrinology and Metabolism, 86(3), 965-971.

Holman, N., Young, B., Gadsby, R. (2015). Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK. Diabetic Medicine, 9(32), 1119-1120.).

Huh, J.Y., Panagiotou, G., Mougios, V., Brinkoetter, M., Vamvini, M.T., Schneider B.E., Mantzoros, C.S. (2012). FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 61,1725-38.

Hussain, A., Ballantyne, C.M., Saeed, A., Virani, S.S. (2020). Triglycerides and ASCVD risk reduction: recent insights and future directions. Current Atherosclerosis Reports, 22(7), 1-10.

Jacobson, T.A., Ito, M.K., Maki, K.C., Orringer, C.E., Bays, H.E., Jones, P.H., Brown, W.V. (2015). National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. Journal of Clinical Lipidology, 9(2), 129-169.

Kim-Dorner, S. J., Deuster, P. A., Zeno, S. A., Remaley, A. T., and Poth, M. (2010). Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?. Metabolism, 59(2), 299-304.

Krivoruchko, A., Zhang, Y., Siewers, V., Chen, Y., Nielsen, J. (2015). Microbial acetyl-CoA metabolism and metabolic engineering. Metabolic engineering, 28, 28-42.

Liu, S., Du, F., Li, X., Wang, M., Duan, R., Zhang, J., Zhang, Q. (2017). Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic Beta cells. PloS one, 12(4), e0175498.

Lv, J., Pan, Y., Li, X., Cheng, D., Ju, H., Tian, J., Zhang, Y. (2015). Study on the distribution and elimination of the new hormone irisin in vivo: new discoveries regarding irisin. Hormone and Metabolic Research, 47(08), 591-595.

Mahmoodnia, L., Sadoughi, M., Ahmadi, A., Kafeshani, M. (2017). Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients. Journal Of Renal Injury Prevention, 6(2), 88.

Ma¡gero, F.R.L., Vasconcellos, L.F., Frazao, L., Bandeira, F. (2021). Irisin Precursor FNDC5 and Glycemic Control in Patients with Type 2 Diabetes. Journal of the Endocrine Society, 5(Suppl 1), A471.

McLaughlin, T., Reaven, G., Abbasi, F., Lamendola, C., Saad, M., Waters, D., Krauss, R.M. (2005). Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. The American Journal of Cardiology, 96(3), 399-404.

Mehrabian, S., Taheri, E., Karkhaneh, M., Qorbani, M., Hosseini, S. (2015). Association of circulating irisin levels with normal weight obesity, glycemic and lipid profile. Journal of Diabetes & Metabolic Disorders, 15(1), 1-6.

Motahari-Tabari, N., Shirvani, M. A., Shirzad-e-Ahoodashty, M., Yousefi-Abdolmaleki, E., Teimourzadeh, M. (2015). The effect of 8 weeks aerobic exercise on insulin resistance in type 2 diabetes: a randomized clinical trial. Global Journal of Health Science, 7(1), 115.

Nuttall, F.Q. (2015). Body mass index: obesity, BMI, and health: a critical review. Nutrition Today, 50(3), 117.

Ommati, N., Nikniaz, L., Mandavi, R. (2019). Association of serum irisin levels with anthropometric, biochemical, and atherogenic indices in healthy adults. Progress In Nutrition, 21(1), 174-182.

Park, K., Ahn, C.W., Park, J.S., Kim, Y., Nam, J.S. (2020). Circulating myokine levels in different stages of glucose intolerance. Medicine, 99(8).

Shah, H.S., Morieri, M. L., Marcovina, S. M., Sigal, R.J., Gerstein, H.C., Wagner, M.J., Doria, A. (2018). Modulation of GLP-1 levels by a genetic variant that regulates the cardiovascular effects of intensive glycemic control in ACCORD. Diabetes Care, 41(2), 348-355.

So, W.Y., Leung, P.S. (2016). Irisin ameliorates hepatic glucose/lipid metabolism and enhances cell survival in insulin-resistant human HepG2 cells through adenosine monophosphate-activated protein kinase signaling. The International Journal of Biochemistry & Cell Biology, 78, 237-247.

Soyal, S., Krempler, F., Oberkofler, H., Patsch, W. (2006). PGC-1 alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia, 49(7), 1477-1488.

Sun, J., Liu, Z., Zhang, Z., Zeng, Z., Kang, W. (2022). The Correlation of Prediabetes and Type 2 Diabetes with Adiposity in Adults. Frontiers in Nutrition, 9, 818263.

Taba¡k, A.G., Herder, C., Rathmann, W., Brunner, E.J., Kivimaki, M. (2012). Prediabetes: a high-risk state for developing diabetes. Lancet, 379(9833), 2279.

Wen, M.S., Wang, C.Y., Lin, S.L., Hung, K.C. (2013). Decrease in irisin in patients with chronic kidney disease. PloS one, 8(5), e64025.

Williamson, D.A. (2018). Prevention of type 2 diabetes: what is the right target population?. Expert Review of Endocrinology & Metabolism, 13(6), 295-305.

Zhang, C., Ding, Z., Lv, G., Li, J., Zhou, P., Zhang, J. (2016). Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis. Journal of Diabetes, 8(1), 56-62.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2022 Array